EudraCT database and EU Clinical Trials Register (EU-CTR)

Similar documents
arena that impact on clinical development

Key concepts of the paediatric regulation and latest developments

Clinical Trials application process, legislation & guidelines

European Medicines Agency Perspective

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

The future clinical trial authorisation process: the new evaluation process

Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd

INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience

New Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012

EFPIA layperson summary Principles that apply to Clinical Trial Transparency. Antonio Ferrari (Chiesi) & Solange Rohou (AZ)

Clinical Trial Safety Reporting requirements

Procedure management of variations

II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD

Report from the Paediatric Committee on its first anniversary

Impact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004

Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)

Monthly statistics report: December 2017

Procedural advice on publication of information on negative opinions and refusals of marketing authorisation applications for human medicinal products

Guidance for participating parties version 2.0, DISCLAIMER

EU Perspective on Regulatory Issues for Biologics

Agenzia Italiana del Farmaco

Safety Measures in the new Pharmacovigilance System

EMA pharmacovigilance system manual

EU Regulation Review: challenges and opportunities for industry

Ethics and Clinical trials EU approach

Brexit Guidance for Stakeholders Human and veterinary medicines

How to support regulatory capacity strengthening in Sub-Saharan Africa EMA Perspective

Annual report 2011 Clinical trials of medicines in humans

Questions And Answers To Support The

Clinical Trial Transparency UK perspective

EU Clinical Trial Regulation A view from the Industry

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

Guideline on good pharmacovigilance practices (GVP)

Regulatory and ethical requirements in medical devices studies. France

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

EU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers

1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States

20 September 2017 EMA/90915/2016 Version 1.3 published 22 September Churchill Place Canary Wharf London E14 5EU United Kingdom

Guideline for participating sponsors

GCP Basics - refresher

EUROPEAN UNION. Brussels, 4 April 2014 (OR. en) 2012/0192 (COD) PE-CONS 2/14 PHARM 5 SAN 9 MI 11 COMPET 12 CODEC 25

Orphan designation in the EU

Public release of clinical information in drug submissions and medical device applications

Regulatory Requirements

PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector

Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

Guideline on the processing of renewals in the centralised procedure

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

The PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member

Global Regulatory Perspective Workshop

Implementing the Directive - from the Swedish Perspective. Kerstin Westermark MD, PhD, Assoc Prof Head of Division of Clinical Trials

Guideline on good pharmacovigilance practices (GVP)

Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples

Review of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance

Explanatory note on general fees payable to the European Medicines Agency

Module 1: Administrative information Application form

Joint statement on public disclosure of results from clinical trials

Supporting Innovation through Scientific Advice

Introduction to the SmPC guideline

Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs

COMMISSION REGULATION (EU)

European Railway Agency SIAFI

The New EU IVDR. Overview of the Main Changes & Clinical Data Requirements. Advance Regulatory Consulting Ltd.

Clinical Research: A Multifaceted Discipline

Quality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)

IVD Regulation 2017/746

CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES

Centralised Procedure and Scientific Advice: an Overview

Update on Real World Evidence Data Collection

Advanced-therapy medicinal products: new competencies in hospital pharmacy Seminar PH4. Relevant Financial Relationships - None

EU Update on Regulatory Developments

European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Regulatory and ethical requirements in medical device studies. Finland

Explanatory Note to GVP Module VII

Chin Koerner Executive Director US Regulatory and Development Policy

Telematics Governance

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

EudraVigilance auditable requirement project

This video gives an overview of the centralised procedure at the European Medicines Agency

Interdependencies of Pharmacovigilance and Regulatory Affairs

The Ethics Appraisal Scheme in Horizon Mr Isidoros Karatzas Head of the Ethics and Reserach Integrity Sector DG RTD

Standard operating procedure

Pharmacovigilance. An agency of the European Union

RAC (EU) Examination Study Checklist

STANDARD OPERATING PROCEDURE SOP 310

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

Environmental Risk Assessment

EudraVigilance access policy for medicines for human use

Good Clinical Practice

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)

The European Medicines Agency: a model of patient/consumer interaction

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

Orphan Drug Development Strategic considerations

Recast Medical Device directives Impacts on materiovigilance

Transcription:

EudraCT database and EU Clinical Trials Register (EU-CTR) Presented by: Laura Pioppo Compliance and Inspection Sector PCWP and HCP WG 16.06.2011 An agency of the European Union

Definitions information systems on clinical trials and medicinal products EudraCT Is a confidential database of interventional clinical trials of medicinal products in the EU/EEA initially accessible only to EU/EEA regulators; EudraPharm Is the database of medicinal products authorised in the European Union, is a public source of information on medicinal products in the EU; EU Clinical Trials Register EU-CTR Is, by law, part of EudraPharm, and it displays public information extracted from the EudraCT database. 2

EudraCT (current Version 8.0, launched on 10 th March 2011) includes data related to Clinical Trials starting from 1 st May 2004 Legal Framework: Article 11 of Directive 2001/20/EC A European database accessible only to the Competent Authorities, European Commission and EMA containing: Extracts from the request for authorisation Any amendments made to the request Any amendments made to the protocol Opinion of the Ethics Committee Declaration of the end of the clinical trial 3 Reference to inspections

Transparency: New Legal requirements have led to the development of EudraCT V 8.0 and EU-CTR Two Regulations: Article 57(2) of Regulation (EC) No 726/2004 Relates to all clinical trials in EudraCT Article 41 of Regulation (EC) No 1901/2006 Relates to paediatric clinical trials 4

Article 57(2) of Regulation (EC) No 726/2004 Where appropriate, the database described under art. 1(l) (EudraPharm) shall also include references to data on clinical trials currently being carried out or already completed, contained in the clinical trials database provided for in Article 11 of Directive 2001/20/EC (EudraCT). The Commission shall, in consultation with the Member States, issue guidelines on data fields which could be included and which may be accessible to the public. 5

Article 41 of Regulation (EC) No 1901/2006 1. The European database created by Article 11 of Directive 2001/20/EC shall include clinical trials carried out in third countries which are contained in an agreed paediatric investigation plan (PIP), in addition to the clinical trials referred to in Articles 1 and 2 of that Directive (... omissis). By way of derogation from the provisions of Article 11 of Directive 2001/20/EC, the Agency shall make public part of the information on paediatric clinical trials entered in the European database. 6

Implementing GLs: Both Regulations require the EC to draw up guidances on the nature of the information to be displayed to the general public. The two implementing guidelines (GLs) published by Commission are the following: Article 57(2) related guideline published - Final July 2008 is 2008/C 168/02 Paediatric guideline published Final February 2009 is 2009/C 28/01 7

Transparency New Legal requirements have lead to the development of future version of EudraCT (V 9.0) To increase trasparency and also as required by Regulations in future there will be the publication of Results related data though the EU-CTR Development EudraCT V 9.0 - Results related data Technical Guidance on Results Information Publication- Draft for public consultation- deadline for comments was 30th September 2010. Comments received have now been consolidated in a new version 8

New Legal requirements General issues Art. 57 Phase II-IV adult trials conducted in the EEA This applies to: Trials of products with or without MAA Art. 41 Phase I-IV paediatric trials + third country trials in a PIP (including phase I trial in adults that are part of PIP) This applies to: The same 9

EU-CTR Has been launched on 22 nd March It contains Protocol related data on: - Clinical trials starting from 01.05.2004 - Phase II/III/IV Adult CTs with at least 1 site in the EEA; - All phases paediatric CTs conducted in EEA; - Paediatric clinical trials that are conducted completed outside of the EEA if they are part of an agreed PIP (including a small % of adult phase I trials if they are part of a PIP) 10

Criteria for publication of CTs in the EU-CTR CTs conducted in adults: If they have a positive NCA decision and a positive IEC opinion and related dates; CTs conducted in paediatric population: If they have a positive NCA decision. IEC opinion can be either positive or negative and the trial will be make public anyway. Related dates will also appear. 11

Number of CTs published on the Register: Number of clinical trials in EU Clinical Trials Register at 15.06.2010: 14739 of which Number of clinical trials with subjects less than 18 years old: 1863 This refers to the number of distinct CTs available in the EU- CTR (No. of protocols). It should be stressed that in EudraCT there at the moment around 29,500 distinct CTs of which around 9,000 are phase I trials conducted in adults that will not made public. 12

Publication of historical data (data from 01.05.2004 to 10.03.2011) Few important things should be taken into account! - The CTs that are missing do not full fill the criteria for publication as the NCA/IEC can be missing or they can be not authorized by the NCAs and IECs, we are closely in contact with the NCAs for improve the quality of the data. - After search is perform the information appearing on the screen is related to the First Past the Post (FPP) record. - Patch 1 has been released two weeks ago 13

Future enhancements in EU-CTR: - Possibility to save the result of your search as a PDF and the ability to forward relevant links to other e-mail addresses (at the moment you can just save 1 record as PDF); - Possibility to Export data as Excel; - Improve the search functionality using Thesaurus; - To add additional filters for search i.e. for rare disease; - Clarify that the first search refer to the FPP; - Interaction with the WHO to make the Register one the registries of the ICTRP and also ICMJE (International Committee of Medical Journal Editors) 14

15 Thank you for your attention!